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INTRODUCTION
50
Over the last two decades, resistance to β-lactams among Enterobacteriaceae has emerged 51 as a major public-health threat. Isolates of Escherichia coli producing extended-spectrum β-52 lactamases are currently responsible for a large proportion of urinary tract infections (UTIs), 53 in the community as well as in the healthcare setting (1-3). In the current era of increasing 54 prevalence of antibiotic resistance, fosfomycin has attracted renewed interest for the 55 treatment of infections caused by multidrug-resistant pathogens, and especially UTIs. 56 Indeed, it has a broad-spectrum antimicrobial activity and a favorable safety profile (4, 5). 57 Fosfomycin-tromethamine, a soluble salt with improved bioavailability over fosfomycin, is 58 currently recommended in single-dose as the first-line drug for the treatment of 59 uncomplicated lower UTIs in Europe (6) and in the United States (7). However, it is unknown 60 whether fosfomycin-tromethamine would be useful for the treatment of pyelonephritis in 61 human, raising the questions of kidney diffusion and breakpoints to be used in 62 pyelonephritis as compared with cystitis. Indeed, the current susceptibility breakpoint of 63 fosfomycin for Enterobacteriaceae is a minimum inhibitory concentration (MIC) of 32 µg/ml 64 according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (8). 65 We previously demonstrated that fosfomycin resistance in E. coli strains from various 66 genetic backgrounds was associated with a decrease of in vitro fitness and in vivo virulence 67 in a murine model of pyelonephritis (9) . In addition, some mutations conferring fosfomycin concentrations (1000-4000 µg/ml) were achieved in urine after oral administration of 3 g of 73 fosfomycin-tromethamine in humans and remained above 100 µg/ml for at least 30-40h 74 (13), but data on concentrations in kidneys are scarce. Here we show that, when given a regimen generating peak and trough levels in plasma in 148 the range of those obtained in human after a single dose of the oral formulation of 149 fosfomycin-tromethamine (approximatively 20 µg/ml and 5 µg/ml, respectively) (17, 18), 
MATERIALS AND METHODS
221
Bacterial strains.
222
Six bacterial strains of E. coli were used ( log10 CFU/g (1.8; 7.0) in start-of-treatment control mice, and 1.9 log10 CFU/g (1.8; 5.7) in fosfomycin-treated mice (P<10 -6
). Lower limit of detection was 1.8 log10 CFU/g of kidney. Time to achieve MGR (Tmax) was significantly prolonged (P < 0.05) at pH 5 as compared with 9 pH 7 for all strains except CO5. 
